Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis.

Por Guldberg, P, Grønbak, K, Aggerholm, A, Platz, A, thor Straten, P, Ahrenkiel, V, Hokland, P, Zeuthen, J
Publicado em 1998

Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis.

Por Jensen, P. H., Cressey, L. I., Gjertsen, B. T., Madsen, P., Mellgren, G., Hokland, P., Gliemann, J., Døskeland, S. O., Lanotte, M., Vintermyr, O. K.
Publicado em 1994

Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia

Por Hjalgrim, L L, Madsen, H O, Melbye, M, Jørgensen, P, Christiansen, M, Andersen, M T, Pallisgaard, N, Hokland, P, Clausen, N, Ryder, L P, Schmiegelow, K, Hjalgrim, H
Publicado em 2002

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

Por Harb, J.G., Neviani, P., Chyla, B.J., Ellis, J.E., Ferenchak, G.J., Oaks, J.J., Walker, C. J., Hokland, P., Roy, DC, Caligiuri, M.A., Marcucci, G., Huettner, C.S., Perrotti, D.
Publicado em 2013

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer

Por Kämpjärvi, K, Mäkinen, N, Kilpivaara, O, Arola, J, Heinonen, H-R, Böhm, J, Abdel-Wahab, O, Lehtonen, H J, Pelttari, L M, Mehine, M, Schrewe, H, Nevanlinna, H, Levine, R L, Hokland, P, Böhling, T, Mecklin, J-P, Bützow, R, Aaltonen, L A, Vahteristo, P
Publicado em 2012